TACTI-003: A RANDOMIZED PHASE IIB STUDY OF EFTILAGIMOD ALPHA (SOLUBLE LAG-3 PROTEIN) AND PEMBROLIZUMAB AS FIRST-LINE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

Irene Brana*, 1Valerii Cheshuk, 2Claus Andrup Kristensen, 3Mania Eugenia Ortega, 4Brieuc Sautois, 5Antonio López-Pousa, 6Judith Christian, 7Willem Lybaert, 8Julio Peguero, 9John Park, 10Robert Metcalf, 11Robert Metcalf, 12Lisle Nabell, 13Bernard Doger de Spéville, 14Jordi Rubí Casadevall, 15Ainara Sonia Rivas, 16Martin Forster, 17Frederic Triebel, 1Vall d’Hebron Institute of Oncology, Barcelona, Spain; 2ARENSIA Exploratory Medicine LLC, Kyiv, Ukraine; 3Rigshospitalet, Copenhagen, Denmark; 4Hospital Universitario Miguel Servet, Zaragoza, Spain; 5Centre Hospitalier Universitaire (CHU), Liège, Belgium; 6Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain; 7Nottingham University Hospitals, NHS, Nottingham, UK; 8VITAZ, Sint-Niklaas, Belgium; 9Oncology Consultants, P.A, Houston, TX, USA; 10Macquarie University Hospital, NSW 2109, Australia; 11The Christie NHS Foundation Trust, Manchester, UK; 12University of Alabama at Birmingham UAB, Birmingham, AL, USA; 13START Madrid, Madrid, Spain; 14Institut Català d’Oncologia – Hospital, Girona, Spain; 15Hospital Universitario Ramón y Cajal, Madrid, Spain; 16UCL Cancer Institute; University College London Hospitals NHS Foundation – The Harley Street Clinic, London, UK; 17Immutep S.A. S., Chatenay Malabry, France

Background
Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MHC class II molecules that mediate antigen-presenting cell (APC) and then CD8 T-cell activation. Data from a non-randomized, phase II trial of efti plus pembrolizumab (TACTI-002) showed encouraging antitumor activity and manageable safety when given as second-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC). TACTI-003 (NCT04811027) is a multicenter, open-label, randomized phase IIb trial to investigate efti plus pembrolizumab in the first line setting for RM-HNSCC.

Methods
A total of 154 patients (pts) are currently being recruited into two cohorts (A+B). In cohort A, pts with tumors that are CPS/CPS ≥ 1 will be randomly assigned 1:1 to receive either efti (30 mg subcutaneously Q2W for initial 6 months, thereafter Q3W) plus pembrolizumab (400 mg intravenously Q6W) for up to two years or pembrolizumab alone. Randomization will be stratified by CPS (1-19 vs. ≥ 20) and ECOG PS (0 vs. 1). Pts with tumors that are CPS<1 will receive efti plus pembrolizumab (cohort B). Imaging will be performed every 9 weeks. The primary endpoint (EP) is the objective response rate (ORR) by RECIST1.1. Secondary EPs include overall survival, ORR according to iRECIST, time to and duration of response, disease control rate, progression-free survival, the occurrence of anti-efti -specific antibodies, safety, and quality of life. Exploratory endpoints comprise biomarkers.

Acknowledgements
- We thank all the participating patients & their families.
- We thank the dedicated clinical trial investigators & their team members.
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided pembrolizumab for the study.
- Sponsored by Immutep.

Trial Registration
The trial identifiers are IMP321-P022 (Sponsor code), Keynote-PNC-34 (MSD code), 2021-000055-39 (EudraCT) and NCT04811027 (ClinicalTrials.gov).

Ethics Approval
This has been approved by relevant Competent Authorities, Ethics Committees, and Institutional Review Boards.